PLK1 and neoplasm: At the age of 6–8 weeks we started to inhibit Plk1 by RNAi or by BI6727-treatment in 3 genetically different cohorts (ApcMin/+, Plk1iKD, ApcMin/+Plk1iKD) and monitored the impact on different relevant parameters including tumor development.